Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07693179
Starting soon Observational

Assessment of Prolonged Pain in Infants With Excessive Crying: Contribution of Infrared Thermal Imaging - The NEOTHERM Pilot Study

NCT07693179 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier de Saint-Denis
Phase
Observational
Started
2026-09
Last updated
2026-09-03

Condition(s) studied

Excessive CryingProlonged Pain

Study summary

NEOTHERM is a multicenter, prospective, observational pilot study examining whether infrared thermal imaging (ITI) can contribute to the assessment of prolonged pain in infants with excessive crying. Thermal measurements of the face and body will be compared with scores obtained using the EDIN behavioral pain and discomfort scale. The study will also examine associations between ITI measures, EDIN scores, and hair cortisol concentrations as a biomarker of prolonged stress, and will describe early motor organization and psychomotor development using General Movements Assessment and Bayley-4. Eighty infants will be enrolled in two comparison groups based on daily crying duration and assessed longitudinally at two standardized visits. The main hypothesis is that ITI will identify cutaneous thermal changes associated with prolonged pain and that these measures will be associated with EDIN scores.

Eligibility

Sex
ALL
Min age
2 Weeks
Max age
6 Weeks
Healthy volunteers
Accepted
Inclusion criteria: * Infants aged 2 to 6 weeks post-term in corrected age at the first assessment. * Born at or after 32 weeks' gestational age. * No known neurological or gastrointestinal disease. * Written informed consent from the holder(s) of parental authority. * Meeting the criteria for one of the following two cohorts: * Excessive-crying (EC) cohort: crying for more than 3 hours per day on at least 3 consecutive days during the 7 days preceding the assessment (modified Wessel criteria), together with at least two of the following three protocol-specified Rome IV-related features: crying without an apparent cause, inconsolable crying, and associated signs including agitation, facial flushing, clenched fists, and/or flexed legs. * Typical-crying (TC) cohort: crying for less than 2 hours per day during the week preceding the assessment. Infants crying for 2 to 3 hours per day during the week preceding the assessment will not be included in either cohort. Exclusion criteria: * Confirmed cerebral lesions identified by ultrasound or magnetic resonance imaging. * Major congenital or chromosomal abnormalities. * Growth faltering. * Birth before 32 weeks' gestational age. * Holder(s) of parental authority who do not speak French. * Lack of written informed consent from the holder(s) of parental authority. * Lack of affiliation with a French social security scheme. * Any situation falling under specific legal protection provisions under French law.

Primary outcome measure(s)

  • Association Between Infrared Thermal Imaging Indices and EDIN Total Score — At baseline (T1) and approximately 8 weeks after baseline (T2)
    Mean skin temperatures will be extracted from predefined body and facial regions of interest. Infrared thermal imaging indices will include absolute bilateral body temperature differences, central-to-peripheral temperature gradients, and intra-facial temperature gradients calculated relative to the forehead. An absolute temperature difference greater than 0.5°C will be considered an abnormal thermal asymmetry. The EDIN is a behavioral scale assessing facial expression, body movements, sleep, interaction, and consolability. Each item is scored from 0 to 3. Higher scores indicate greater pain- or discomfort-related behaviors; a total score of 5 or higher indicates probable prolonged pain. Concordance between infrared thermal imaging indices and EDIN total scores will be quantified using Spearman rank correlation coefficients at each assessment. Thermal images will be analyzed by an external assessor blinded to the EDIN score and cohort classification.

Trial sites (3)

FacilityCityRegionStatus
Centre Médico-Psychologique Périnatalité et Petite Enfance Brantôme Paris Île-de-France Region
Centre Hospitalier de Saint-Denis - Department of Neonatology Saint-Denis Île-de-France Region
Centre Hospitalier de Saint-Denis - Department of Perinatal Psychiatry Saint-Denis Île-de-France Region

More Centre Hospitalier de Saint-Denis trials in France

Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning Recruiting
Evaluate a Local Program to Reduce the Risky Use of Screens by Children Under 3, Based on the Experience of Parents Who Successfully Stopped This Exposure. Starting soon
Requests for Voluntary Termination and Medical Termination of Pregnancy for Maternal, Psychological or Social Reasons At the Women's Center ( La Maison Des Femmes) in Saint-Denis : Active, not recruiting
Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa Recruiting
Sexual Health of Sub-Saharan African Migrant Women Recently Diagnosed With HIV in Île-de-France: Missed Opportunities for Prevention Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07693179 on ClinicalTrials.gov ↗ ← All trials in France